HER2 Testing in Endometrial Serous Carcinoma

This targeted therapeutic approach was recently endorsed by the National Comprehensive Cancer Network clinical guidelines. There is a growing interest among clinicians to obtain HER2 testing in endometrial serous carcinoma, and pathologists need to be prepared to recognize the unique characteristics of HER2 protein expression and gene amplification in these tumors and apply specific...

Cited by: 3  Author: Natalia Sobe
Publish Year: 2020

HER2 Testing and Reporting in Endometrial Serous...
https://journals.lww.com/intjgynpathology/Abstract...-

Abstract. Anti-HER2 therapy has recently emerged as an effective targeted treatment approach for patients with advanced-stage and recurrent endometrial serous carcinomas, resulting in significantly prolonged progression-free and overall survival when combined with the standard chemotherapy regimens. Compared with treatment-naive patients, patients with advanced-stage and recurrent endometrial serous carcinomas who express HER2-positive tumors have significantly longer survival with anti-HER2 treatment, often leading to a cure or long-term disease control or stabilization.
Human epidermal growth factor receptor 2 targeted therapy in endometrial cancer

May 10, 2014

This is a keyword search result for "Human epidermal growth factor receptor 2 targeted therapy in endometrial cancer". The search results include articles and studies that have been published in this area. The articles are from reputable sources such as PubMed and Google Scholar. Each article provides a summary of the research findings, and links to full-text versions are available for further reading. The articles cover various aspects of the topic, including mechanisms of action, clinical trials, and outcomes. The search results are useful for researchers and clinicians interested in the latest developments in this field.

Significant intratumoral heterogeneity of human epidermal growth factor receptor 2

May 10, 2014

This is a keyword search result for "Significant intratumoral heterogeneity of human epidermal growth factor receptor 2". The search results include articles and studies that have been published in this area. The articles are from reputable sources such as PubMed and Google Scholar. Each article provides a summary of the research findings, and links to full-text versions are available for further reading. The articles cover various aspects of the topic, including mechanisms of action, clinical trials, and outcomes. The search results are useful for researchers and clinicians interested in the latest developments in this field.

Management of Early-Stage Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

Jun 13, 2021

This is a keyword search result for "Management of Early-Stage Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer". The search results include articles and studies that have been published in this area. The articles are from reputable sources such as PubMed and Google Scholar. Each article provides a summary of the research findings, and links to full-text versions are available for further reading. The articles cover various aspects of the topic, including mechanisms of action, clinical trials, and outcomes. The search results are useful for researchers and clinicians interested in the latest developments in this field.
Name of Journal: World Journal of Clinical Oncology
Manuscript NO: 6498
Manuscript Type: MINIREVIEWS

Human epidermal growth factor receptor 2 targeted therapy in endometrial cancer:
Clinical and pathological perspectives

Seito A et al. HER2 targeted therapy in endometrial cancer

Ayumi Seito, Hiroshi Yohida, Tadaaki Nishikawa, Kan Yonemori

Abstract
Endometrial cancer is the most common gynecological cancer in developed countries, and its incidence has increased. The majority of patients with endometrial cancer have an early disease and favorable prognosis; however, a significant proportion of endometrial cancer, which mainly comprises high-grade or type II endometrial cancer such as serous, clear cell, and carcinosarcoma, shows advanced/recurrent disease and
Target Therapies for Uterine Carcinomas: Current ... 
Based on our results, the differential expression and accessibility of epithelial cell adhesion molecule-1 on metastatic/chemotherapy-resistant CS cells in comparison to normal tissues and Human Epidermal Growth Factor Receptor 2 (HER2) open up new possibilities in the field of target therapy.
Cited by: 19  Author: Salvatore Giovanni Vitale, Antonio Simon... 
Publish Year: 2017

Human epidermal growth factor receptor-2 expression in ... 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317932
May 16, 2014 - The HER-2 (c-erbB-2) oncoprotein is a 185-kDa transmembrane cell surface receptor of the human epidermal growth factor family and usually expressed on epithelial cells. The tyrosine kinase activity of HER-2 intracellular domain triggers signal transduction that has important roles in cell proliferation, differentiation, and survival. As a ... 
Cited by: 10  Author: Xiangjiao Meng, Ranben Wang, Zhaqin ... 
Publish Year: 2014

Targeted Therapies in HER2-Positive Breast Cancer – a ... 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC26557822
Jul 05, 2021 - The majority of the adenocarcinomas are hormone receptor (HR) positive and approximately 20% of the malignant breast tumors show an overexpression of human epidermal growth factor receptor 2 (HER2) on their cell surface. Identification of receptor expression offers treatment options for individualized targeted therapies.
Cited by: 23  Author: Amelie Schramm, Nikolaus De Gregorio,... 
Publish Year: 2016

Significant intratumoral heterogeneity of human epidermal ... 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4832862
Feb 19, 2016 - The assessment of human epidermal growth factor receptor 2 (HER 2) status is crucial for selecting patients with gastric cancer who may benefit from HER 2-targeted therapy. Accurate assessment using biopsy specimens is important for patients with advanced-stage cancer.
Cited by: 18  Author: Kazuki Kanavama, Hiroshi Imai, Misao Y...